Senior management

Gunilla Osswald
Gunilla Osswald
President and Chief Executive Officer

In current position since 2014, employed since 2013. More than 30 years of experience from drug development. Successfully brought projects from pre-clinical and clinical development to regulatory approval and market introduction as well as managed in- and outlicensing of drug projects. Leading positions at Astra/AstraZeneca during 1985-2013, including Vice President with the responsibility of the product portfolio in neurodegenerative diseases

Born: 1961
Education: Pharmacist and Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden
Other current assignments: Board member of PledPharma AB (publ) and SpineMedical AB and deputy board member of LPB Sweden AB
Prior assignments (past five years): Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB
Holdings: 12,800 B-shares and 5,818 call options entitle to the acquisition of 87,270 B-shares

Jan Mattsson
Jan Mattsson
Vice President Finance, Chief Financial Officer

In current position since 2017. More than 30 years of experience in business and administration, including CFO for Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment AB Kinnevik

Born: 1960
Education: MBA, University of Örebro, Sweden, 1984
Other current assignments: –
Prior assignments (past five years): Board member of Sefina Finance AB, Sefina Svensk Pantbelåning AB and Humidus AB
Holdings: 15,000 B-shares (privately and through the company Almsäter Interim Management AB) and 1 818 call options entitle to the acquisition of 27,270 B-shares

Christina Astrén Eriksson
Christina Astrén Eriksson
IR and Communications Director

Contracted since 2015 and for investor relations since 2017. More than 30 years of experience in communications, including communications director at Pfizer, AstraZeneca, Wyeth and Pharmacia and interim IR & communications manager at Orexo AB (publ)

Born: 1959
Education: Degree in journalism, Stockholm University, Sweden, 1984; Diploma from IHR (Institutet för Högre Kommunikations- och Reklamutbildning), Stockholm University, Sweden, 1988
Other current assignments: –
Prior assignments (past five years): –
Holdings: 25,000 B-shares (through the company C Astrén AB)

Hans Basun
Hans Basun
Vice President Clinical Development, Chief Medical Officer

In current position since 2007. More than 20 years of experience from the pharmaceutical industry in leading position in clinical research at Astra Arcus/AstraZeneca. Background as Senior Consultant at Huddinge University Hospital and Professor at Uppsala University Hospital, Sweden

Born: 1949
Education: Medical degree and residency in psychiatry and geriatrics, Associate Professor at Karolinska Institutet and Adjunct Professor at Uppsala University
Other current assignments: Deputy board member of SpineMedical AB
Prior assignments (past five years): –
Holdings: 20,823 B-shares and 1,818 call options entitle to the acquisition of 27,270 B-shares

Johanna Fälting
Johanna Fälting
Vice President Translational Science & Pharmacology

In current position since January 2018, employed since 2012. 15 years of experience of neuroscience/pharmacology, translational science and development in the global pharma and biotech industry

Born: 1972
Education: Ph.D. in Physiology, Stockholm University 2001; Licentiate degree in physiology, Stockholm University 1997; Master’s degree in biology, Stockholm University, Sweden, 1995
Other current assignments: Deputy board member of Biozoul AB
Prior assignments (past five years): –
Holdings: 10,000 B-shares and 1,818 call options entitle to the acquisition of 27,270 B-shares

Lars Lannfelt
Lars Lannfelt
Senior Vice President University Collaborations

Co-opted member of the Senior Management Team. In current position since September 2018. Founder of BioArctic with Pär Gellerfors in 2003. Board member and a number of assignments and roles in the company since then. More than 35 years of experience from research in Alzheimer´s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University 2001; Senior Professor at Uppsala University 2016 and member of the Royal Swedish Academy of Sciences since 2004

Born: 1949
Education: Medical degree 1978; specialist in psychiatry 1987; doctoral thesis at Karolinska Institutet 1990; Associate Professor of Neurogenetics at Karolinska Institutet 1993; specialist in geriatrics 2000
Other assignments: Board member of Demban AB and LPB Sweden AB
Prior assignments (past five years): Board member of Demban Förvaltning AB, SpineMedical Sverige AB, SpineMedical AB and LPB Sweden Holding AB
Holdings: 8,639,998 A-shares and 22,848,159 B-shares through Demban AB

Mikael Moge
Mikael Moge
Vice President Chemistry, Manufacturing & Control and Protein Chemistry

In current position since January 2018, employed since 2012. 20 years of experience from drug development and 15 years of experience as research and development manager within process development and GMP manufacturing. Previously section manager at process R&D at AstraZeneca

Born: 1967
Education: Master of Engineering chemical engineering, KTH (Royal Institute of Technology), Ph.D. of Science organic chemistry, KTH, Stockholm, Sweden
Other current assignments: –
Prior assignments (past five years): –
Holdings: 455 call options entitle to the acquisition of 6,825 B-shares

Christer Möller
Christer Möller
Vice President Pre-Clinical Development, Chief Scientific Officer

In current position since 2006. 20 years of experience from developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies; Zymenex A/S among others. In addition, comprehensive academic experience having pursued research projects concerning growth factors and preclinical research in diabetes

Born: 1959
Education: B.Sc in Biology Stockholm University, 1983; Ph.D. in Medical Science, Karolinska Institutet, Sweden, 1992
Other current assignments: –
Prior assignments (past five years): –
Holdings: 16,500 B-shares and 1,818 call options entitle to the acquisition of 27,270 B-shares

Nora Sjödin
Nora Sjödin
Vice President Regulatory Affairs

In current position since January 2018, employed in 2017. 25 years of experience from leading positions in global Regulatory Affairs in companies such as AstraZeneca, NDA Regulatory Service and most recent from Pharmalink. The extensive regulatory affairs experience includes regulatory matters from early development projects to approved pharmaceuticals on the market

Born: 1957
Education: B.Sc, General Nursing, SRN
Other current assignments: –
Prior assignments (past five years): –
Holdings: –

The Senior Management Team as of September 1, 2018.

Holdings in BioArctic AB as of December 31, 2017.